Androgen Deprivation Therapy and High dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Disease (cancer type)

Prostate Cancer

Contact information

  • Michigan: Maria Pappas (248) 553-0606

Patient Selection Criteria

Patients must have a Gleason score of 7-10 and stage T1c-T2b and a PSA of <50 ng/ml; or a Gleason score of 6 and stage T2c-T4 or >50% positive biopsies and a PSA < 50 ng/ml; or a Gleason score of 6 and stage T1c-T2b and a PSA > 20 ng/ml. Other criteria apply.

Research sponsor

RTOG

Reference ID#

RTOG 0924

State(s)

  • Michigan
Back
To top